Investment Analysts’ Weekly Ratings Updates for GSK (GSK)

A number of firms have modified their ratings and price targets on shares of GSK (LON: GSK) recently:

• 9/15/2026 – GSK had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a GBX 2,000 price target on the stock.
• 9/15/2026 – GSK had its price target raised by Berenberg Bank from GBX 2,000 to GBX 2,200. They now have a “hold” rating on the stock.
• 9/8/2026 – GSK had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a GBX 1,975 price target on the stock.
• 9/2/2026 – GSK had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a GBX 2,000 price target on the stock.
• 8/19/2026 – GSK had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a GBX 2,000 price target on the stock.
• 8/4/2026 – GSK had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a GBX 2,000 price target on the stock.
• 7/29/2026 – GSK had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a GBX 2,500 price target on the stock.
• 7/27/2026 – GSK had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a GBX 1,950 price target on the stock.

Insiders Place Their Bets

In other GSK news, insider Jeannie Lee bought 802 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Vishal Sikka purchased 1,266 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of GBX 5,069 per share, with a total value of £64,173.54. Insiders have acquired 3,625 shares of company stock worth $13,494,563 in the last three months. 0.20% of the stock is owned by insiders.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.